Jasper Therapeutics, Inc.
JSPR · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.05 | -0.10 | -0.14 |
| FCF Yield | -45.51% | -35.36% | -6.81% | -5.08% |
| EV / EBITDA | -1.70 | -0.85 | -11.22 | -9.91 |
| Quality | ||||
| ROIC | -96.98% | -46.29% | -38.46% | -22.60% |
| Gross Margin | 0.00% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 0.91 | 0.58 | 1.08 | 0.87 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -66.10% | -7.59% | -48.19% | -21.03% |
| Safety | ||||
| Net Debt / EBITDA | 1.38 | 2.15 | 3.24 | 4.67 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,802.56 | -966.13 | -617.43 | -513.38 |